A new model of pharmacovigilance? A pilot study

A. Zancan, C. Locatelli, F. Ramella, P. Tatoni, G. Bacis, S. Vecchio, L. Manzo

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

This multicenter study tested the actuation of a new model of pharmacovigilance, focused on three pharmacological wide-used categories (non-steroidal anti-inflammatory drugs, NSAID, oral anticoagulants, and antihypertensive drugs). Besides the traditional way of pharmacovigilance, an active investigation was performed, using a phone-structured interview. Patients discharged from the participating hospitals were included into the study, if their prescribed therapy included some of the above drugs and after informed consent. Three hundred subjects were interviewed, 100 for each pharmacological category. For a period of six months after patient's discharge from the hospital, a traditional pharmacovigilance survey was carried out. About 30 days after discharge from the hospital, patients were interviewed by the medical staff and data recorded. NSAID group stratification evidenced a significant percentage of severe haemorrhage among the patients who were using acetylsalicylic acid (ASA) as antiaggregant (6.8%) compared to the patients who were using non-ASA NSAID, at therapeutic dosage (1.8%). From this data, it seems that the active pharmacovigilance model was able to better highlight a real problem for the NSAID category, in particular it evidenced a pharmacological subclass (ASA) more prone to cause ADR than expected from literature data related to whole pharmacological class. Given the required economical effort, this pharmacovigilance method could take place as a selected tool when pharmacovigilance signals from the international databases become consistent or for new wide-used drugs, to screen potentially dangerous pharmacological subclasses, normally "hidden" because of a "camouflage" among ADRs of the entire pharmacological class.

Original languageEnglish
Pages (from-to)451-455
Number of pages5
JournalBiomedicine and Pharmacotherapy
Volume63
Issue number6
DOIs
Publication statusPublished - Jul 2009

Fingerprint

Pharmacovigilance
Non-Steroidal Anti-Inflammatory Agents
Pharmacology
Patient Discharge
Aspirin
Pharmaceutical Preparations
Medical Staff
Informed Consent
Anticoagulants
Antihypertensive Agents
Multicenter Studies
Anti-Inflammatory Agents
Databases
Interviews
Hemorrhage
Acids
Therapeutics

Keywords

  • ADR
  • Model
  • Pharmacovigilance

ASJC Scopus subject areas

  • Pharmacology

Cite this

A new model of pharmacovigilance? A pilot study. / Zancan, A.; Locatelli, C.; Ramella, F.; Tatoni, P.; Bacis, G.; Vecchio, S.; Manzo, L.

In: Biomedicine and Pharmacotherapy, Vol. 63, No. 6, 07.2009, p. 451-455.

Research output: Contribution to journalArticle

Zancan, A. ; Locatelli, C. ; Ramella, F. ; Tatoni, P. ; Bacis, G. ; Vecchio, S. ; Manzo, L. / A new model of pharmacovigilance? A pilot study. In: Biomedicine and Pharmacotherapy. 2009 ; Vol. 63, No. 6. pp. 451-455.
@article{018acedb348649e695129fcfcd425fcb,
title = "A new model of pharmacovigilance? A pilot study",
abstract = "This multicenter study tested the actuation of a new model of pharmacovigilance, focused on three pharmacological wide-used categories (non-steroidal anti-inflammatory drugs, NSAID, oral anticoagulants, and antihypertensive drugs). Besides the traditional way of pharmacovigilance, an active investigation was performed, using a phone-structured interview. Patients discharged from the participating hospitals were included into the study, if their prescribed therapy included some of the above drugs and after informed consent. Three hundred subjects were interviewed, 100 for each pharmacological category. For a period of six months after patient's discharge from the hospital, a traditional pharmacovigilance survey was carried out. About 30 days after discharge from the hospital, patients were interviewed by the medical staff and data recorded. NSAID group stratification evidenced a significant percentage of severe haemorrhage among the patients who were using acetylsalicylic acid (ASA) as antiaggregant (6.8{\%}) compared to the patients who were using non-ASA NSAID, at therapeutic dosage (1.8{\%}). From this data, it seems that the active pharmacovigilance model was able to better highlight a real problem for the NSAID category, in particular it evidenced a pharmacological subclass (ASA) more prone to cause ADR than expected from literature data related to whole pharmacological class. Given the required economical effort, this pharmacovigilance method could take place as a selected tool when pharmacovigilance signals from the international databases become consistent or for new wide-used drugs, to screen potentially dangerous pharmacological subclasses, normally {"}hidden{"} because of a {"}camouflage{"} among ADRs of the entire pharmacological class.",
keywords = "ADR, Model, Pharmacovigilance",
author = "A. Zancan and C. Locatelli and F. Ramella and P. Tatoni and G. Bacis and S. Vecchio and L. Manzo",
year = "2009",
month = "7",
doi = "10.1016/j.biopha.2008.07.091",
language = "English",
volume = "63",
pages = "451--455",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson SAS",
number = "6",

}

TY - JOUR

T1 - A new model of pharmacovigilance? A pilot study

AU - Zancan, A.

AU - Locatelli, C.

AU - Ramella, F.

AU - Tatoni, P.

AU - Bacis, G.

AU - Vecchio, S.

AU - Manzo, L.

PY - 2009/7

Y1 - 2009/7

N2 - This multicenter study tested the actuation of a new model of pharmacovigilance, focused on three pharmacological wide-used categories (non-steroidal anti-inflammatory drugs, NSAID, oral anticoagulants, and antihypertensive drugs). Besides the traditional way of pharmacovigilance, an active investigation was performed, using a phone-structured interview. Patients discharged from the participating hospitals were included into the study, if their prescribed therapy included some of the above drugs and after informed consent. Three hundred subjects were interviewed, 100 for each pharmacological category. For a period of six months after patient's discharge from the hospital, a traditional pharmacovigilance survey was carried out. About 30 days after discharge from the hospital, patients were interviewed by the medical staff and data recorded. NSAID group stratification evidenced a significant percentage of severe haemorrhage among the patients who were using acetylsalicylic acid (ASA) as antiaggregant (6.8%) compared to the patients who were using non-ASA NSAID, at therapeutic dosage (1.8%). From this data, it seems that the active pharmacovigilance model was able to better highlight a real problem for the NSAID category, in particular it evidenced a pharmacological subclass (ASA) more prone to cause ADR than expected from literature data related to whole pharmacological class. Given the required economical effort, this pharmacovigilance method could take place as a selected tool when pharmacovigilance signals from the international databases become consistent or for new wide-used drugs, to screen potentially dangerous pharmacological subclasses, normally "hidden" because of a "camouflage" among ADRs of the entire pharmacological class.

AB - This multicenter study tested the actuation of a new model of pharmacovigilance, focused on three pharmacological wide-used categories (non-steroidal anti-inflammatory drugs, NSAID, oral anticoagulants, and antihypertensive drugs). Besides the traditional way of pharmacovigilance, an active investigation was performed, using a phone-structured interview. Patients discharged from the participating hospitals were included into the study, if their prescribed therapy included some of the above drugs and after informed consent. Three hundred subjects were interviewed, 100 for each pharmacological category. For a period of six months after patient's discharge from the hospital, a traditional pharmacovigilance survey was carried out. About 30 days after discharge from the hospital, patients were interviewed by the medical staff and data recorded. NSAID group stratification evidenced a significant percentage of severe haemorrhage among the patients who were using acetylsalicylic acid (ASA) as antiaggregant (6.8%) compared to the patients who were using non-ASA NSAID, at therapeutic dosage (1.8%). From this data, it seems that the active pharmacovigilance model was able to better highlight a real problem for the NSAID category, in particular it evidenced a pharmacological subclass (ASA) more prone to cause ADR than expected from literature data related to whole pharmacological class. Given the required economical effort, this pharmacovigilance method could take place as a selected tool when pharmacovigilance signals from the international databases become consistent or for new wide-used drugs, to screen potentially dangerous pharmacological subclasses, normally "hidden" because of a "camouflage" among ADRs of the entire pharmacological class.

KW - ADR

KW - Model

KW - Pharmacovigilance

UR - http://www.scopus.com/inward/record.url?scp=68649101853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68649101853&partnerID=8YFLogxK

U2 - 10.1016/j.biopha.2008.07.091

DO - 10.1016/j.biopha.2008.07.091

M3 - Article

VL - 63

SP - 451

EP - 455

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

IS - 6

ER -